Ali Salavati1,2, Fenghai Duan3, Bradley S Snyder4, Bo Wei5, Sina Houshmand6, Benjapa Khiewvan6,7, Adam Opanowski8, Charles B Simone9, Barry A Siegel10, Mitchell Machtay11, Abass Alavi12. 1. Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Salav006@umn.edu. 2. Department of Radiology, University of Minnesota, Minneapolis, MN, USA. Salav006@umn.edu. 3. Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI, USA. 4. Center for Statistical Sciences, Brown University School of Public Health, Providence, RI, USA. 5. Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA, USA. 6. Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 7. Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 8. American College of Radiology, ACR Center for Research and Innovation, Philadelphia, PA, USA. 9. Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD, USA. 10. Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St, Louis, MO, USA. 11. Department of Radiation Oncology, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH, USA. 12. Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Abass.Alavi@uphs.upenn.edu.
Abstract
PURPOSE: In recent years, multiple studies have demonstrated the value of volumetric FDG-PET/CT parameters as independent prognostic factors in patients with non-small cell lung cancer (NSCLC). We aimed to determine the optimal cut-off points of pretreatment volumetric FDG-PET/CT parameters in predicting overall survival (OS) in patients with locally advanced NSCLC and to recommend imaging biomarkers appropriate for routine clinical applications. METHODS: Patients with inoperable stage IIB/III NSCLC enrolled in ACRIN 6668/RTOG 0235 were included. Pretreatment FDG-PET scans were quantified using semiautomatic adaptive contrast-oriented thresholding and local-background partial-volume-effect-correction algorithms. For each patient, the following indices were measured: metabolic tumor volume (MTV), total lesion glycolysis (TLG), SUVmax, SUVmean, partial-volume-corrected TLG (pvcTLG), and pvcSUVmean for the whole-body, primary tumor, and regional lymph nodes. The association between each index and patient outcome was assessed using Cox proportional hazards regression. Optimal cut-off points were estimated using recursive binary partitioning in a conditional inference framework and used in Kaplan-Meier curves with log-rank testing. The discriminatory ability of each index was examined using time-dependent receiver operating characteristic (ROC) curves and corresponding area under the curve (AUC(t)). RESULTS: The study included 196 patients. Pretreatment whole-body and primary tumor MTV, TLG, and pvcTLG were independently prognostic of OS. Optimal cut-off points were 175.0, 270.9, and 35.5 cm3 for whole-body TLG, pvcTLG, and MTV, and were 168.2, 239.8, and 17.4 cm3 for primary tumor TLG, pvcTLG, and MTV, respectively. In time-dependent ROC analysis, AUC(t) for MTV and TLG were uniformly higher than that of SUV measures over all time points. Primary tumor and whole-body parameters demonstrated similar patterns of separation for those patients above versus below the optimal cut-off points in Kaplan-Meier curves and in time-dependent ROC analysis. CONCLUSION: We demonstrated that pretreatment whole-body and primary tumor volumetric FDG-PET/CT parameters, including MTV, TLG, and pvcTLG, are strongly prognostic for OS in patients with locally advanced NSCLC, and have similar discriminatory ability. Therefore, we believe that, after validation in future trials, the derived optimal cut-off points for primary tumor volumetric FDG-PET/CT parameters, or their more refined versions, could be incorporated into routine clinical practice, and may provide more accurate prognostication and staging based on tumor metabolic features.
PURPOSE: In recent years, multiple studies have demonstrated the value of volumetric FDG-PET/CT parameters as independent prognostic factors in patients with non-small cell lung cancer (NSCLC). We aimed to determine the optimal cut-off points of pretreatment volumetric FDG-PET/CT parameters in predicting overall survival (OS) in patients with locally advanced NSCLC and to recommend imaging biomarkers appropriate for routine clinical applications. METHODS:Patients with inoperable stage IIB/III NSCLC enrolled in ACRIN 6668/RTOG 0235 were included. Pretreatment FDG-PET scans were quantified using semiautomatic adaptive contrast-oriented thresholding and local-background partial-volume-effect-correction algorithms. For each patient, the following indices were measured: metabolic tumor volume (MTV), total lesion glycolysis (TLG), SUVmax, SUVmean, partial-volume-corrected TLG (pvcTLG), and pvcSUVmean for the whole-body, primary tumor, and regional lymph nodes. The association between each index and patient outcome was assessed using Cox proportional hazards regression. Optimal cut-off points were estimated using recursive binary partitioning in a conditional inference framework and used in Kaplan-Meier curves with log-rank testing. The discriminatory ability of each index was examined using time-dependent receiver operating characteristic (ROC) curves and corresponding area under the curve (AUC(t)). RESULTS: The study included 196 patients. Pretreatment whole-body and primary tumorMTV, TLG, and pvcTLG were independently prognostic of OS. Optimal cut-off points were 175.0, 270.9, and 35.5 cm3 for whole-body TLG, pvcTLG, and MTV, and were 168.2, 239.8, and 17.4 cm3 for primary tumorTLG, pvcTLG, and MTV, respectively. In time-dependent ROC analysis, AUC(t) for MTV and TLG were uniformly higher than that of SUV measures over all time points. Primary tumor and whole-body parameters demonstrated similar patterns of separation for those patients above versus below the optimal cut-off points in Kaplan-Meier curves and in time-dependent ROC analysis. CONCLUSION: We demonstrated that pretreatment whole-body and primary tumor volumetric FDG-PET/CT parameters, including MTV, TLG, and pvcTLG, are strongly prognostic for OS in patients with locally advanced NSCLC, and have similar discriminatory ability. Therefore, we believe that, after validation in future trials, the derived optimal cut-off points for primary tumor volumetric FDG-PET/CT parameters, or their more refined versions, could be incorporated into routine clinical practice, and may provide more accurate prognostication and staging based on tumor metabolic features.
Authors: Shengri Liao; Bill C Penney; Kristen Wroblewski; Hao Zhang; Cassie A Simon; Rony Kampalath; Ming-Chi Shih; Naoko Shimada; Sheng Chen; Ravi Salgia; Daniel E Appelbaum; Kenji Suzuki; Chin-Tu Chen; Yonglin Pu Journal: Eur J Nucl Med Mol Imaging Date: 2011-09-23 Impact factor: 9.236
Authors: Jose G Bazan; Fenghai Duan; Bradley S Snyder; Dunstan Horng; Edward E Graves; Barry A Siegel; Mitchell Machtay; Billy W Loo Journal: Eur J Nucl Med Mol Imaging Date: 2016-09-19 Impact factor: 9.236
Authors: Geoffrey A Geiger; Miranda B Kim; Eric P Xanthopoulos; Daniel A Pryma; Surbhi Grover; John P Plastaras; Corey J Langer; Charles B Simone; Ramesh Rengan Journal: Clin Lung Cancer Date: 2013-10-08 Impact factor: 4.785
Authors: Irene A Burger; Ruben Casanova; Seraina Steiger; Lars Husmann; Paul Stolzmann; Martin W Huellner; Alessandra Curioni; Sven Hillinger; C Ross Schmidtlein; Alex Soltermann Journal: J Nucl Med Date: 2016-01-28 Impact factor: 10.057
Authors: Tae Ryool Koo; Sung Ho Moon; Yu Jin Lim; Ja Young Kim; Yeonjoo Kim; Tae Hyun Kim; Kwan Ho Cho; Ji-Youn Han; Young Joo Lee; Tak Yun; Heung Tae Kim; Jin Soo Lee Journal: Radiat Oncol Date: 2014-12-13 Impact factor: 3.481
Authors: Maja Guberina; Wilfried Eberhardt; Martin Stuschke; Thomas Gauler; Clemens Aigner; Martin Schuler; Georgios Stamatis; Dirk Theegarten; Walter Jentzen; Ken Herrmann; Christoph Pöttgen Journal: Eur J Nucl Med Mol Imaging Date: 2019-02-01 Impact factor: 9.236
Authors: Kimiteru Ito; Heiko Schöder; Rebecca Teng; John L Humm; Ai Ni; Jedd D Wolchok; Wolfgang A Weber Journal: Eur J Nucl Med Mol Imaging Date: 2018-11-28 Impact factor: 9.236